Literature DB >> 9370953

Gene expression and synthesis of fibronectin isoforms in rat hepatic stellate cells. Comparison with liver parenchymal cells and skin fibroblasts.

G Xu1, T Niki, I Virtanen, V Rogiers, P De Bleser, A Geerts.   

Abstract

Fibronectins are multifunctional glycoproteins that are important components of the extracellular matrix in normal and fibrotic liver. Multiple fibronectin isoforms are generated from a single gene by alternative splicing of the primary transcript at the domains EIIIA, EIIIB, and V. The aim of this study was to investigate the fibronectin isoforms expressed by activated hepatic stellate cells, the most important connective tissue-producing cells in injured liver. Hepatocytes and skin fibroblasts were also studied for comparison. Activation of hepatic stellate cells in vivo was induced by injecting CCl4 twice weekly for 3 weeks. Activation in vitro was achieved by culturing cells on plastic. The level of activation was evaluated by alpha-smooth muscle actin immunocytochemistry. Steady-state levels of fibronectin isoform messenger RNA were examined by Northern hybridization analysis using specific cDNA probes for the EIIIA, EIIIB, and V domains. The de novo synthesis of fibronectin isoforms was examined by metabolic labelling and immunoprecipitation using domain-specific monoclonal antibodies. Fibronectin transcripts were not detectable in freshly isolated hepatic stellate cells from normal liver. Cultured hepatic stellate cells, as well as skin fibroblasts, expressed EIIIA+, EIIIB+, and V95+ transcripts. They were detectable as early as day 3 and increased with time in culture. At 3 days in culture, more than 90 per cent of stellate cells were alpha-smooth muscle actin-positive. In vivo activated hepatic stellate cells expressed EIIIA+ and V95+ transcripts; EIIIB+ fibronectin mRNA was absent. Less than 20 per cent of in vivo activated stellate cells expressed alpha-smooth muscle actin. Freshly isolated parenchymal cells from normal liver as well as from CCl4-treated liver expressed V95+ transcripts, but were negative for EIIIA or EIIIB fibronectin mRNA. Immunoprecipitation results were in accordance with Northern hybridization analysis. Hepatic stellate cells in culture synthesized and secreted fibronectin molecules that contained EIIIA, EIIIB, and V fragments. Our results indicate that hepatic stellate cells synthesize and secrete fibronectin isoforms that are distinct from those of parenchymal cells.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9370953     DOI: 10.1002/(SICI)1096-9896(199709)183:1<90::AID-PATH1105>3.0.CO;2-J

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  9 in total

1.  Rolipram attenuates bile duct ligation-induced liver injury in rats: a potential pathogenic role of PDE4.

Authors:  Leila Gobejishvili; Shirish Barve; Katja Breitkopf-Heinlein; Yan Li; JingWen Zhang; Diana V Avila; Steven Dooley; Craig J McClain
Journal:  J Pharmacol Exp Ther       Date:  2013-07-25       Impact factor: 4.030

2.  Effect of liver dysfunction on circulating sclerostin.

Authors:  Yumie Rhee; Won Jin Kim; Ki Jun Han; Sung Kil Lim; Se Hwa Kim
Journal:  J Bone Miner Metab       Date:  2013-10-15       Impact factor: 2.626

3.  Activated hepatic stellate cells are dependent on self-collagen, cleaved by membrane type 1 matrix metalloproteinase for their growth.

Authors:  Naoko Kubo Birukawa; Kazuyuki Murase; Yasushi Sato; Akemi Kosaka; Akihiro Yoneda; Hiroki Nishita; Ryosuke Fujita; Miyuki Nishimura; Takafumi Ninomiya; Keiko Kajiwara; Miyono Miyazaki; Yusuke Nakashima; Sigenori Ota; Yuya Murakami; Yasunobu Tanaka; Kenjiro Minomi; Yasuaki Tamura; Yoshiro Niitsu
Journal:  J Biol Chem       Date:  2014-05-27       Impact factor: 5.157

4.  Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver.

Authors:  Bruno Costa-Silva; Nicole M Aiello; Allyson J Ocean; Swarnima Singh; Haiying Zhang; Basant Kumar Thakur; Annette Becker; Ayuko Hoshino; Milica Tešić Mark; Henrik Molina; Jenny Xiang; Tuo Zhang; Till-Martin Theilen; Guillermo García-Santos; Caitlin Williams; Yonathan Ararso; Yujie Huang; Gonçalo Rodrigues; Tang-Long Shen; Knut Jørgen Labori; Inger Marie Bowitz Lothe; Elin H Kure; Jonathan Hernandez; Alexandre Doussot; Saya H Ebbesen; Paul M Grandgenett; Michael A Hollingsworth; Maneesh Jain; Kavita Mallya; Surinder K Batra; William R Jarnagin; Robert E Schwartz; Irina Matei; Héctor Peinado; Ben Z Stanger; Jacqueline Bromberg; David Lyden
Journal:  Nat Cell Biol       Date:  2015-05-18       Impact factor: 28.824

Review 5.  Cellular sources of extracellular matrix in hepatic fibrosis.

Authors:  Rebecca G Wells
Journal:  Clin Liver Dis       Date:  2008-11       Impact factor: 6.126

Review 6.  Current understanding of osteoporosis associated with liver disease.

Authors:  Inaam A Nakchbandi; Schalk W van der Merwe
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-11       Impact factor: 46.802

7.  Higher intestinal and circulatory lactate associated NOX2 activation leads to an ectopic fibrotic pathology following microcystin co-exposure in murine fatty liver disease.

Authors:  Sutapa Sarkar; Punnag Saha; Ratanesh K Seth; Ayan Mondal; Dipro Bose; Diana Kimono; Muayad Albadrani; Avik Mukherjee; Dwayne E Porter; Geoff I Scott; Shuo Xiao; Bryan Brooks; John Ferry; Mitzi Nagarkatti; Prakash Nagarkatti; Saurabh Chatterjee
Journal:  Comp Biochem Physiol C Toxicol Pharmacol       Date:  2020-08-08       Impact factor: 3.228

8.  Fibronectin protects from excessive liver fibrosis by modulating the availability of and responsiveness of stellate cells to active TGF-β.

Authors:  Nina Kawelke; Matthaeus Vasel; Carla Sens; Anja von Au; Steven Dooley; Inaam A Nakchbandi
Journal:  PLoS One       Date:  2011-11-28       Impact factor: 3.240

9.  Fibronectin expression is critical for liver fibrogenesis in vivo and in vitro.

Authors:  Xiao-Ya Liu; Rui-Xia Liu; Fei Hou; Li-Jian Cui; Chun-Yun Li; Cheng Chi; Entong Yi; Yan Wen; Cheng-Hong Yin
Journal:  Mol Med Rep       Date:  2016-08-25       Impact factor: 2.952

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.